From Clinical Analytics Platform TriNetX Raises $40M to Speed Drug Trials:

Gadi Lachman, TriNetX CEO

Gadi Lachman, TriNetX CEO—

Courtesy photo

Underwriters and Partners

Xconomy Insight

From Our Editors · Special Report
Xcelerating Life Sciences Philadelphia: Special Report
Becoming the Cell & Gene Therapy Hub

Sponsored · Webinar
Nov. 12 – High-Throughput Assessment of Compound-Induced Cardiotoxicity Using Human iPSC-Derived Cardiomyocytes
Provide an in vitro drug-induced proarrhythmia assessment & strengthen pharmacological safety profiles of drug candidates
Eurofins DiscoverX

Sponsored · Whitepaper
What’s Next in Neuroscience Therapies
New approaches & tech are on the horizon that could change how researchers and clinicians approach brain and neurological disorders

Xconomy on Demand

We offer a number of ways to subscribe for free!